Navis, Anna C., van Lith, Sanne A. M., van Duijnhoven, Sander M. J., de Pooter, Maaike, Yetkin-Arik, Bahar, Wesseling, Pieter, Hendriks, Wiljan J. A. J., Venselaar, Hanka ORCID: 0000-0001-9824-6559, Timmer, Marco, van Cleef, Patricia, Henegouwen, Paul van Bergen En, Best, Myron G., Wurdinger, Thomas D., Tops, Bastiaan B. J. and Leenders, William P. J. (2015). Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein. Acta Neuropathol., 130 (1). S. 131 - 145. NEW YORK: SPRINGER. ISSN 1432-0533

Full text not available from this repository.

Abstract

MET has gained interest as a therapeutic target for a number of malignancies because of its involvement in tumorigenesis, invasion and metastasis. At present, a number of inhibitors, both antibodies against MET or its ligand hepatocyte growth factor, and small molecule MET tyrosine kinase inhibitors are in clinical trials. We here describe a novel variant of MET that is expressed in 6 % of high-grade gliomas. Characterization of this mutation in a glioma cell line revealed that it consists of an intronic deletion, resulting in a splice event connecting an intact splice donor site in exon 6 with the next splice acceptor site being that of exon 9. The encoded protein lacks parts of the extracellular IPT domains 1 and 2, encoded by exons 7 and 8, resulting in a novel pseudo-IPT and is named MET Delta 7-8. MET Delta 7-8 is located predominantly in the cytosol and is constitutively active. The auto-activating nature of MET Delta 7-8, in combination with a lack of transmembrane localization, renders MET Delta 7-8 not targetable using antibodies, although the protein is efficiently deactivated by MET-specific tyrosine kinase inhibitors. Testing of MET-expressing tumors for the presence of this variant may be important for treatment decision making.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Navis, Anna C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
van Lith, Sanne A. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
van Duijnhoven, Sander M. J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
de Pooter, MaaikeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Yetkin-Arik, BaharUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wesseling, PieterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hendriks, Wiljan J. A. J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Venselaar, HankaUNSPECIFIEDorcid.org/0000-0001-9824-6559UNSPECIFIED
Timmer, MarcoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
van Cleef, PatriciaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Henegouwen, Paul van Bergen EnUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Best, Myron G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wurdinger, Thomas D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tops, Bastiaan B. J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Leenders, William P. J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-400132
DOI: 10.1007/s00401-015-1420-5
Journal or Publication Title: Acta Neuropathol.
Volume: 130
Number: 1
Page Range: S. 131 - 145
Date: 2015
Publisher: SPRINGER
Place of Publication: NEW YORK
ISSN: 1432-0533
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
HEPATOCYTE GROWTH-FACTOR; CELL LUNG-CANCER; TYROSINE KINASE RECEPTOR; SCATTER FACTOR-RECEPTOR; C-MET; JUXTAMEMBRANE DOMAIN; GENE AMPLIFICATION; PHASE-II; EXPRESSION; EGFRMultiple languages
Clinical Neurology; Neurosciences; PathologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/40013

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item